Advising claimant on resorting to the DIFC courts to obtain Mareva injunctions as part of a global recovery strategy.
Advising claimant on resorting to the DIFC courts to obtain Mareva injunctions as part of a global recovery strategy.
Complex Commercial & Corporate Disputes
Advising a large holding company on defending against injunctions filed in London, New York, and the UAE simultaneously.
Advising a large holding company on defending against injunctions filed in London, New York, and the UAE simultaneously.
Representation in a USD 40M vicarious liability dispute in the UAE courts between a UAE major retailer and a Korean MNC.
Representation in a USD 40M vicarious liability dispute in the UAE courts between a UAE major retailer and a Korean MNC.
Representation in a USD 120M dispute between an HNW individual and a major bank related to the illegitimate use of financial instruments.
Representation in a USD 120M dispute between an HNW individual and a major bank related to the illegitimate use of financial instruments.
Representation in a USD 20M shareholder dispute between an exiting shareholder and a global engineering firm regarding valuation.
Representation in a USD 20M shareholder dispute between an exiting shareholder and a global engineering firm regarding valuation.
Representation in a USD 120M derivative shareholder claim for a Canadian shareholder arising from allegations of corporate fraud.
Representation in a USD 120M derivative shareholder claim for a Canadian shareholder arising from allegations of corporate fraud.
Representing a shareholder of a Fin-Tech firm in pursuing allegations of breach of governance and fiduciary duties.
Representing a shareholder of a Fin-Tech firm in pursuing allegations of breach of governance and fiduciary duties.
Representation in a USD 60M capital markets dispute between a shareholder of a listed firm and a block trade acquirer.
Representation in a USD 60M capital markets dispute between a shareholder of a listed firm and a block trade acquirer.
Representation in a USD 40M dispute between an institutional investor and a pharmaceutical firm for misrepresentation of assets.
Representation in a USD 40M dispute between an institutional investor and a pharmaceutical firm for misrepresentation of assets.